Identification

Name
Rosoxacin
Accession Number
DB00817  (APRD00369)
Type
Small Molecule
Groups
Approved, Investigational
Description

Rosoxacin is a quinolone derivative antibiotic for the treatment of bacterial infection of respiratory tract, urinary tract, GI, CNS and immuno compromised patients. Rosoxacin is known to be effective against penicillin resistant strains and is a single dose orally administered drug, which avoids all complications of parenteral administration seen with penicillin, especially anaphylactic shock.

Structure
Thumb
Synonyms
  • Acrosoxacin
  • ROS
  • Rosoxacin
  • Rosoxacine
  • Rosoxacino
  • Rosoxacinum
  • Roxadyl
External IDs
TO 133 / Win 35213
International/Other Brands
Eradacil (Sanofi-Aventis)
Categories
UNII
3Y1OT3J4NW
CAS number
40034-42-2
Weight
Average: 294.3047
Monoisotopic: 294.100442324
Chemical Formula
C17H14N2O3
InChI Key
XBPZXDSZHPDXQU-UHFFFAOYSA-N
InChI
InChI=1S/C17H14N2O3/c1-2-19-10-14(17(21)22)16(20)13-4-3-12(9-15(13)19)11-5-7-18-8-6-11/h3-10H,2H2,1H3,(H,21,22)
IUPAC Name
1-ethyl-4-oxo-7-(pyridin-4-yl)-1,4-dihydroquinoline-3-carboxylic acid
SMILES
CCN1C=C(C(O)=O)C(=O)C2=C1C=C(C=C2)C1=CC=NC=C1

Pharmacology

Indication

For the treatment of bacterial infection of respiratory tract, urinary tract, GI, CNS and immuno compromised patients.

Structured Indications
Not Available
Pharmacodynamics

Rosoxacin is a nonfluorinated quinolone antibiotic. Its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Rosoxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria.

Mechanism of action

Rosoxacin binds to and inhibits the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination.

TargetActionsOrganism
ADNA gyrase subunit B
inhibitor
Escherichia coli (strain K12)
ADNA topoisomerase 4 subunit A
inhibitor
Escherichia coli (strain K12)
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Enteric bacteria and other eubacteria
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Rosoxacin.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Rosoxacin.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Rosoxacin.Experimental, Illicit
AcarboseRosoxacin may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AceclofenacAceclofenac may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
AcemetacinAcemetacin may increase the neuroexcitatory activities of Rosoxacin.Approved, Experimental, Investigational
AcenocoumarolRosoxacin may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the neuroexcitatory activities of Rosoxacin.Approved, Vet Approved
AdapaleneAdapalene may increase the neuroexcitatory activities of Rosoxacin.Approved
AlbiglutideRosoxacin may increase the hypoglycemic activities of Albiglutide.Approved
AlclofenacAlclofenac may increase the neuroexcitatory activities of Rosoxacin.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Rosoxacin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Rosoxacin.Experimental, Investigational
AlmasilateAlmasilate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlminoprofenAlminoprofen may increase the neuroexcitatory activities of Rosoxacin.Experimental
AlogliptinRosoxacin may increase the hypoglycemic activities of Alogliptin.Approved
AloglutamolAloglutamol can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AluminiumAluminium can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ambroxol acefyllinateThe metabolism of Ambroxol acefyllinate can be decreased when combined with Rosoxacin.Experimental, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Rosoxacin.Approved
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Rosoxacin.Approved
AndrographolideAndrographolide may increase the neuroexcitatory activities of Rosoxacin.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Rosoxacin.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Rosoxacin.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Rosoxacin.Investigational
AnisodamineAnisodamine may increase the neuroexcitatory activities of Rosoxacin.Investigational
AntipyrineAntipyrine may increase the neuroexcitatory activities of Rosoxacin.Approved
ApocyninApocynin may increase the neuroexcitatory activities of Rosoxacin.Investigational
ApremilastApremilast may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Rosoxacin.Investigational
AzapropazoneAzapropazone may increase the neuroexcitatory activities of Rosoxacin.Withdrawn
AzelastineAzelastine may increase the neuroexcitatory activities of Rosoxacin.Approved
BalsalazideBalsalazide may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Rosoxacin.Approved, Investigational
BendazacBendazac may increase the neuroexcitatory activities of Rosoxacin.Experimental
BenorilateBenorilate may increase the neuroexcitatory activities of Rosoxacin.Experimental
BenoxaprofenBenoxaprofen may increase the neuroexcitatory activities of Rosoxacin.Withdrawn
BenzydamineBenzydamine may increase the neuroexcitatory activities of Rosoxacin.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Rosoxacin.Approved, Vet Approved
BevoniumBevonium may increase the neuroexcitatory activities of Rosoxacin.Experimental
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
BromfenacBromfenac may increase the neuroexcitatory activities of Rosoxacin.Approved
BromocriptineRosoxacin may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BucillamineBucillamine may increase the neuroexcitatory activities of Rosoxacin.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Rosoxacin.Approved
BufexamacBufexamac may increase the neuroexcitatory activities of Rosoxacin.Experimental
BumadizoneBumadizone may increase the neuroexcitatory activities of Rosoxacin.Experimental
Calcium AcetateCalcium Acetate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium ChlorideCalcium Chloride can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium CitrateCalcium Citrate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium glubionateCalcium glubionate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium GluceptateCalcium Gluceptate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium gluconateCalcium gluconate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Calcium lactateCalcium lactate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateCalcium lactate gluconate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium laevulateCalcium laevulate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium pangamateCalcium pangamate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium PhosphateCalcium Phosphate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium silicateCalcium silicate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CanagliflozinRosoxacin may increase the hypoglycemic activities of Canagliflozin.Approved
CarprofenCarprofen may increase the neuroexcitatory activities of Rosoxacin.Approved, Vet Approved, Withdrawn
CaseinCasein can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CastanospermineCastanospermine may increase the neuroexcitatory activities of Rosoxacin.Experimental
CelecoxibCelecoxib may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
ChloroquineChloroquine may increase the neuroexcitatory activities of Rosoxacin.Approved, Vet Approved
ChlorpropamideRosoxacin may increase the hypoglycemic activities of Chlorpropamide.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the neuroexcitatory activities of Rosoxacin.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Rosoxacin.Approved, Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Rosoxacin.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Rosoxacin.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Rosoxacin.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Rosoxacin.Approved
ClonixinClonixin may increase the neuroexcitatory activities of Rosoxacin.Approved
ClorindioneRosoxacin may increase the anticoagulant activities of Clorindione.Experimental
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Rosoxacin.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Rosoxacin.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Rosoxacin.Approved
CurcuminCurcumin may increase the neuroexcitatory activities of Rosoxacin.Investigational
D-LimoneneD-Limonene may increase the neuroexcitatory activities of Rosoxacin.Investigational
DapagliflozinRosoxacin may increase the hypoglycemic activities of Dapagliflozin.Approved
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Rosoxacin.Approved
DesonideThe risk or severity of adverse effects can be increased when Desonide is combined with Rosoxacin.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Rosoxacin.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Rosoxacin.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Rosoxacin.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Rosoxacin.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Rosoxacin.Vet Approved
DiclofenacDiclofenac may increase the neuroexcitatory activities of Rosoxacin.Approved, Vet Approved
DicoumarolRosoxacin may increase the anticoagulant activities of Dicoumarol.Approved
DidanosineThe serum concentration of Didanosine can be decreased when it is combined with Rosoxacin.Approved
DifenpiramideDifenpiramide may increase the neuroexcitatory activities of Rosoxacin.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Rosoxacin.Approved
DiflunisalDiflunisal may increase the neuroexcitatory activities of Rosoxacin.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Rosoxacin.Approved, Investigational
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Rosoxacin.Approved
DiphenadioneRosoxacin may increase the anticoagulant activities of Diphenadione.Experimental
DisopyramideRosoxacin may increase the hypoglycemic activities of Disopyramide.Approved
DroxicamDroxicam may increase the neuroexcitatory activities of Rosoxacin.Approved
DulaglutideRosoxacin may increase the hypoglycemic activities of Dulaglutide.Approved
DuvelisibDuvelisib may increase the neuroexcitatory activities of Rosoxacin.Investigational
DyphyllineThe metabolism of Dyphylline can be decreased when combined with Rosoxacin.Approved
E-6201E-6201 may increase the neuroexcitatory activities of Rosoxacin.Investigational
EmpagliflozinRosoxacin may increase the hypoglycemic activities of Empagliflozin.Approved
EpirizoleEpirizole may increase the neuroexcitatory activities of Rosoxacin.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Rosoxacin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Rosoxacin.Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Rosoxacin.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Rosoxacin.Approved
EtanerceptEtanercept may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
EthenzamideEthenzamide may increase the neuroexcitatory activities of Rosoxacin.Experimental
Ethyl biscoumacetateRosoxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
EtoricoxibEtoricoxib may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
ExenatideRosoxacin may increase the hypoglycemic activities of Exenatide.Approved, Investigational
exisulindexisulind may increase the neuroexcitatory activities of Rosoxacin.Investigational
FelbinacFelbinac may increase the neuroexcitatory activities of Rosoxacin.Experimental
FenbufenFenbufen may increase the neuroexcitatory activities of Rosoxacin.Approved
FenoprofenFenoprofen may increase the neuroexcitatory activities of Rosoxacin.Approved
FentiazacFentiazac may increase the neuroexcitatory activities of Rosoxacin.Experimental
FeprazoneFeprazone may increase the neuroexcitatory activities of Rosoxacin.Experimental
Ferric CarboxymaltoseThe serum concentration of Rosoxacin can be decreased when it is combined with Ferric Carboxymaltose.Approved
Ferric CitrateThe serum concentration of Rosoxacin can be decreased when it is combined with Ferric Citrate.Approved, Investigational
Ferric pyrophosphateThe serum concentration of Rosoxacin can be decreased when it is combined with Ferric pyrophosphate.Approved
Ferulic acidFerulic acid may increase the neuroexcitatory activities of Rosoxacin.Experimental
FloctafenineFloctafenine may increase the neuroexcitatory activities of Rosoxacin.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when fluasterone is combined with Rosoxacin.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Rosoxacin.Approved
FluindioneRosoxacin may increase the anticoagulant activities of Fluindione.Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Rosoxacin.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Rosoxacin.Approved, Investigational
FlunixinFlunixin may increase the neuroexcitatory activities of Rosoxacin.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the neuroexcitatory activities of Rosoxacin.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Rosoxacin.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Rosoxacin.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Rosoxacin.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Rosoxacin.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Rosoxacin.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Rosoxacin.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Rosoxacin.Approved
FlurbiprofenFlurbiprofen may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Rosoxacin.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Rosoxacin.Approved
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Rosoxacin.Approved, Investigational, Withdrawn
GliclazideRosoxacin may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideRosoxacin may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideRosoxacin may increase the hypoglycemic activities of Glipizide.Approved
GlyburideRosoxacin may increase the hypoglycemic activities of Glyburide.Approved
GuacetisalGuacetisal may increase the neuroexcitatory activities of Rosoxacin.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with Rosoxacin.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Rosoxacin.Investigational
HigenamineHigenamine may increase the neuroexcitatory activities of Rosoxacin.Investigational
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Rosoxacin.Approved, Vet Approved
HydrotalciteHydrotalcite can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
IbuprofenIbuprofen may increase the neuroexcitatory activities of Rosoxacin.Approved
IbuproxamIbuproxam may increase the neuroexcitatory activities of Rosoxacin.Withdrawn
IcatibantIcatibant may increase the neuroexcitatory activities of Rosoxacin.Approved
Imidazole salicylateImidazole salicylate may increase the neuroexcitatory activities of Rosoxacin.Experimental
IndobufenIndobufen may increase the neuroexcitatory activities of Rosoxacin.Investigational
IndomethacinIndomethacin may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
IndoprofenIndoprofen may increase the neuroexcitatory activities of Rosoxacin.Withdrawn
Insulin AspartRosoxacin may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirRosoxacin may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineRosoxacin may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineRosoxacin may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanRosoxacin may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproRosoxacin may increase the hypoglycemic activities of Insulin Lispro.Approved
IronThe serum concentration of Rosoxacin can be decreased when it is combined with Iron.Approved
Iron DextranThe serum concentration of Rosoxacin can be decreased when it is combined with Iron Dextran.Approved, Vet Approved
Iron saccharateThe serum concentration of Rosoxacin can be decreased when it is combined with Iron saccharate.Approved
IsoxicamIsoxicam may increase the neuroexcitatory activities of Rosoxacin.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Rosoxacin.Investigational
KebuzoneKebuzone may increase the neuroexcitatory activities of Rosoxacin.Experimental
KetoprofenKetoprofen may increase the neuroexcitatory activities of Rosoxacin.Approved, Vet Approved
KetorolacKetorolac may increase the neuroexcitatory activities of Rosoxacin.Approved
Lanthanum carbonateThe serum concentration of Rosoxacin can be decreased when it is combined with Lanthanum carbonate.Approved
LeflunomideLeflunomide may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
LiraglutideRosoxacin may increase the hypoglycemic activities of Liraglutide.Approved
LisofyllineLisofylline may increase the neuroexcitatory activities of Rosoxacin.Investigational
LonazolacLonazolac may increase the neuroexcitatory activities of Rosoxacin.Experimental
LornoxicamLornoxicam may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Loteprednol is combined with Rosoxacin.Approved
LoxoprofenLoxoprofen may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
LumiracoxibLumiracoxib may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium HydroxideMagnesium Hydroxide can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium salicylateThe serum concentration of Rosoxacin can be decreased when it is combined with Magnesium salicylate.Approved
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Magnesium SulfateThe serum concentration of Rosoxacin can be decreased when it is combined with Magnesium Sulfate.Approved, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MasoprocolMasoprocol may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Rosoxacin.Investigational
MecaserminRosoxacin may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the neuroexcitatory activities of Rosoxacin.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Rosoxacin.Approved
Mefenamic acidMefenamic acid may increase the neuroexcitatory activities of Rosoxacin.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Rosoxacin.Vet Approved
MeloxicamMeloxicam may increase the neuroexcitatory activities of Rosoxacin.Approved, Vet Approved
MesalazineMesalazine may increase the neuroexcitatory activities of Rosoxacin.Approved
MetamizoleMetamizole may increase the neuroexcitatory activities of Rosoxacin.Investigational, Withdrawn
MetforminRosoxacin may increase the hypoglycemic activities of Metformin.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Rosoxacin.Approved, Vet Approved
MifepristoneRosoxacin may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolRosoxacin may increase the hypoglycemic activities of Miglitol.Approved
MizoribineMizoribine may increase the neuroexcitatory activities of Rosoxacin.Investigational
MofebutazoneMofebutazone may increase the neuroexcitatory activities of Rosoxacin.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Rosoxacin.Approved, Vet Approved
Mycophenolate mofetilMycophenolate mofetil may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Rosoxacin.Approved
NabumetoneNabumetone may increase the neuroexcitatory activities of Rosoxacin.Approved
NafamostatNafamostat may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
NaftifineNaftifine may increase the neuroexcitatory activities of Rosoxacin.Approved
NaproxenNaproxen may increase the neuroexcitatory activities of Rosoxacin.Approved, Vet Approved
NateglinideRosoxacin may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Rosoxacin.Investigational
NepafenacNepafenac may increase the neuroexcitatory activities of Rosoxacin.Approved
NifenazoneNifenazone may increase the neuroexcitatory activities of Rosoxacin.Experimental
Niflumic AcidNiflumic Acid may increase the neuroexcitatory activities of Rosoxacin.Approved
NimesulideNimesulide may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may increase the neuroexcitatory activities of Rosoxacin.Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Rosoxacin.Investigational
OlopatadineOlopatadine may increase the neuroexcitatory activities of Rosoxacin.Approved
OlsalazineOlsalazine may increase the neuroexcitatory activities of Rosoxacin.Approved
OrgoteinOrgotein may increase the neuroexcitatory activities of Rosoxacin.Vet Approved
OxaprozinOxaprozin may increase the neuroexcitatory activities of Rosoxacin.Approved
OxyphenbutazoneOxyphenbutazone may increase the neuroexcitatory activities of Rosoxacin.Approved, Withdrawn
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Rosoxacin.Approved
ParecoxibParecoxib may increase the neuroexcitatory activities of Rosoxacin.Approved
ParthenolideParthenolide may increase the neuroexcitatory activities of Rosoxacin.Investigational
PentamidineRosoxacin may increase the hypoglycemic activities of Pentamidine.Approved
PhenindioneRosoxacin may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonRosoxacin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazonePhenylbutazone may increase the neuroexcitatory activities of Rosoxacin.Approved, Vet Approved
PimecrolimusPimecrolimus may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
PioglitazoneRosoxacin may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirfenidonePirfenidone may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
PiroxicamPiroxicam may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
PirprofenPirprofen may increase the neuroexcitatory activities of Rosoxacin.Experimental
PramlintideRosoxacin may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PranoprofenPranoprofen may increase the neuroexcitatory activities of Rosoxacin.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Rosoxacin.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Rosoxacin.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Rosoxacin.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Rosoxacin.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Rosoxacin.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Rosoxacin.Experimental, Investigational
ProbenecidThe serum concentration of Rosoxacin can be increased when it is combined with Probenecid.Approved
ProglumetacinProglumetacin may increase the neuroexcitatory activities of Rosoxacin.Experimental
PropacetamolPropacetamol may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
PropyphenazonePropyphenazone may increase the neuroexcitatory activities of Rosoxacin.Experimental
ProquazoneProquazone may increase the neuroexcitatory activities of Rosoxacin.Experimental
PTC299PTC299 may increase the neuroexcitatory activities of Rosoxacin.Investigational
QuinaprilThe serum concentration of Rosoxacin can be decreased when it is combined with Quinapril.Approved, Investigational
QuinineRosoxacin may increase the hypoglycemic activities of Quinine.Approved
RepaglinideRosoxacin may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
ResveratrolResveratrol may increase the neuroexcitatory activities of Rosoxacin.Approved, Experimental, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Rosoxacin.Approved
RofecoxibRofecoxib may increase the neuroexcitatory activities of Rosoxacin.Investigational, Withdrawn
RosiglitazoneRosoxacin may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SalicylamideSalicylamide may increase the neuroexcitatory activities of Rosoxacin.Approved
Salicylic acidSalicylic acid may increase the neuroexcitatory activities of Rosoxacin.Approved, Vet Approved
SalsalateSalsalate may increase the neuroexcitatory activities of Rosoxacin.Approved
SaxagliptinRosoxacin may increase the hypoglycemic activities of Saxagliptin.Approved
SemapimodSemapimod may increase the neuroexcitatory activities of Rosoxacin.Investigational
SeratrodastSeratrodast may increase the neuroexcitatory activities of Rosoxacin.Approved
SerrapeptaseSerrapeptase may increase the neuroexcitatory activities of Rosoxacin.Investigational
SevelamerSevelamer can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SitagliptinRosoxacin may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SRT501SRT501 may increase the neuroexcitatory activities of Rosoxacin.Investigational
Strontium ranelateThe serum concentration of Rosoxacin can be decreased when it is combined with Strontium ranelate.Approved
SucralfateThe serum concentration of Rosoxacin can be decreased when it is combined with Sucralfate.Approved
SulfadiazineRosoxacin may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleRosoxacin may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfasalazineSulfasalazine may increase the neuroexcitatory activities of Rosoxacin.Approved
SulfisoxazoleRosoxacin may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may increase the neuroexcitatory activities of Rosoxacin.Approved
SunitinibRosoxacin may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuprofenSuprofen may increase the neuroexcitatory activities of Rosoxacin.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the neuroexcitatory activities of Rosoxacin.Experimental
TarenflurbilTarenflurbil may increase the neuroexcitatory activities of Rosoxacin.Investigational
TenidapTenidap may increase the neuroexcitatory activities of Rosoxacin.Experimental
TenoxicamTenoxicam may increase the neuroexcitatory activities of Rosoxacin.Approved
TepoxalinTepoxalin may increase the neuroexcitatory activities of Rosoxacin.Vet Approved
TeriflunomideTeriflunomide may increase the neuroexcitatory activities of Rosoxacin.Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Rosoxacin.Approved
Tiaprofenic acidTiaprofenic acid may increase the neuroexcitatory activities of Rosoxacin.Approved
TinoridineTinoridine may increase the neuroexcitatory activities of Rosoxacin.Investigational
TioclomarolRosoxacin may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Rosoxacin.Approved
TolazamideRosoxacin may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideRosoxacin may increase the hypoglycemic activities of Tolbutamide.Approved
Tolfenamic AcidTolfenamic Acid may increase the neuroexcitatory activities of Rosoxacin.Approved
TolmetinTolmetin may increase the neuroexcitatory activities of Rosoxacin.Approved
TranilastTranilast may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Rosoxacin.Approved, Vet Approved
TribenosideTribenoside may increase the neuroexcitatory activities of Rosoxacin.Experimental
TriptolideTriptolide may increase the neuroexcitatory activities of Rosoxacin.Investigational
TromethamineTromethamine can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Rosoxacin.Approved
ValdecoxibValdecoxib may increase the neuroexcitatory activities of Rosoxacin.Investigational, Withdrawn
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Rosoxacin.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Rosoxacin.Approved
WarfarinRosoxacin may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenZaltoprofen may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
ZileutonZileuton may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational, Withdrawn
ZomepiracZomepirac may increase the neuroexcitatory activities of Rosoxacin.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB14955
KEGG Drug
D02305
PubChem Compound
287180
PubChem Substance
46508469
ChemSpider
253208
ChEBI
131715
ChEMBL
CHEMBL291157
Therapeutic Targets Database
DAP000929
PharmGKB
PA164776843
ATC Codes
J01MB01 — Rosoxacin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedPreventionOral Leukoplakia1
Not AvailableNot Yet RecruitingHealth Services ResearchNicotine / Oxidative Stress1
Not AvailableRecruitingTreatmentPituitary Neoplasms1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)290 °CPhysProp
water solubility0.0209 mg/mL at 25 °CMEYLAN,WM et al. (1996)
logP3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.102 mg/mLALOGPS
logP1.85ALOGPS
logP1.9ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)6.18ChemAxon
pKa (Strongest Basic)4.9ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area70.5 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity83.06 m3·mol-1ChemAxon
Polarizability30.8 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9953
Blood Brain Barrier+0.8044
Caco-2 permeable+0.6365
P-glycoprotein substrateNon-substrate0.5522
P-glycoprotein inhibitor INon-inhibitor0.8418
P-glycoprotein inhibitor IINon-inhibitor0.7855
Renal organic cation transporterNon-inhibitor0.8055
CYP450 2C9 substrateNon-substrate0.7741
CYP450 2D6 substrateNon-substrate0.8696
CYP450 3A4 substrateNon-substrate0.7172
CYP450 1A2 substrateNon-inhibitor0.7953
CYP450 2C9 inhibitorNon-inhibitor0.864
CYP450 2D6 inhibitorNon-inhibitor0.9328
CYP450 2C19 inhibitorNon-inhibitor0.8731
CYP450 3A4 inhibitorNon-inhibitor0.9181
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7267
Ames testNon AMES toxic0.8588
CarcinogenicityNon-carcinogens0.8638
BiodegradationNot ready biodegradable0.9751
Rat acute toxicity2.3043 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9583
hERG inhibition (predictor II)Non-inhibitor0.8496
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Quinoline carboxylic acids
Direct Parent
Quinoline carboxylic acids
Alternative Parents
Phenylpyridines / Hydroquinolones / Hydroquinolines / Pyridinecarboxylic acids / Benzenoids / Vinylogous amides / Heteroaromatic compounds / Monocarboxylic acids and derivatives / Carboxylic acids / Azacyclic compounds
show 5 more
Substituents
Quinoline-3-carboxylic acid / 4-phenylpyridine / Dihydroquinolone / Dihydroquinoline / Pyridine carboxylic acid / Pyridine carboxylic acid or derivatives / Pyridine / Benzenoid / Heteroaromatic compound / Vinylogous amide
show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Magnesium ion binding
Specific Function
DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, inc...
Gene Name
gyrB
Uniprot ID
P0AES6
Uniprot Name
DNA gyrase subunit B
Molecular Weight
89949.195 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Zweerink MM, Edison A: Inhibition of Micrococcus luteus DNA gyrase by norfloxacin and 10 other quinolone carboxylic acids. Antimicrob Agents Chemother. 1986 Apr;29(4):598-601. [PubMed:3010848]
  4. Hirai K, Aoyama H, Suzue S, Irikura T, Iyobe S, Mitsuhashi S: Isolation and characterization of norfloxacin-resistant mutants of Escherichia coli K-12. Antimicrob Agents Chemother. 1986 Aug;30(2):248-53. [PubMed:3532944]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function
Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule. MukB stimulates th...
Gene Name
parC
Uniprot ID
P0AFI2
Uniprot Name
DNA topoisomerase 4 subunit A
Molecular Weight
83830.455 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Zweerink MM, Edison A: Inhibition of Micrococcus luteus DNA gyrase by norfloxacin and 10 other quinolone carboxylic acids. Antimicrob Agents Chemother. 1986 Apr;29(4):598-601. [PubMed:3010848]

Drug created on June 13, 2005 07:24 / Updated on November 07, 2017 01:43